Publications by APAC RA-EWG

Analysis report201320142015

Analysis Report identifies differences in regulatory requirements on drug development from IND (if applicable), clinical trial, NDA and to manufacturing/ post approval (including GMP evaluation system). The report will be updated annually so as to maintain the information be accurate.

4th APAC (April, 2015)

has been advocating the concept of good registration management, under which execution of both Good Submission Practices (GSubP) and Good Review Practices (GRevP) by the applicants and the reviewers, respectively, will enhance the performance of both submission and review, leading to efficient and quick drug registration/approval. As the industry initiative and proposals, the team prepared the APAC GSubP guideline and APAC position paper documents.

APAC GSubP Guideline

APAC GSubP guideline is developed to improve the quality of submission dossier and its management.

APAC Good Registration Management Position Paper

APAC position paper is intended to further improve the transparency, predictability and timeliness of drug review by facilitating communication with the reviewers.

3rd APAC (April, 2014)

In order to realize the APAC's mission, RA EWG produced two deliverables focusing on the new drug application (NDA) stage.

APAC GRegiP Policy Document& Appendix

The policy document on good registration practice, which can be applied to the APAC regions, contains seven proposals which would make both submission and review of the NDA better.

Convergence of NDA Requirements Proposal Document& Fact Sheet

The proposal document on convergence of NDA Requirements describes the common issues and proposed approaches to improve the regulatory requirements for NDA.

2nd APAC (April, 2013)

order to realize the APAC's mission, RA-EWG produced two deliverables, Analysis Report (refer to above) and Concept Paper.

Concept Paper

Concept Paper provides with the fundamental framework in the activities and outlines a strategic multi-year approach.